The biological and clinical significance of emerging SARS-CoV-2 variants
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
[HTML][HTML] SARS-CoV-2 variants, spike mutations and immune escape
Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) genome are expected to be either deleterious and swiftly purged or relatively …
CoV-2) genome are expected to be either deleterious and swiftly purged or relatively …
[HTML][HTML] SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
JS Turner, JA O'Halloran, E Kalaidina, W Kim… - Nature, 2021 - nature.com
Abstract SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-
19 1, 2, 3, 4, 5. The dynamics of antibody-secreting plasmablasts and germinal centre B …
19 1, 2, 3, 4, 5. The dynamics of antibody-secreting plasmablasts and germinal centre B …
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape,–, have activity
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …
[HTML][HTML] SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
C Motozono, M Toyoda, J Zahradnik, A Saito… - Cell host & …, 2021 - cell.com
Many SARS-CoV-2 variants with naturally acquired mutations have emerged. These
mutations can affect viral properties such as infectivity and immune resistance. Although the …
mutations can affect viral properties such as infectivity and immune resistance. Although the …
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
Detection of a SARS-CoV-2 variant of concern in South Africa
Continued uncontrolled transmission of SARS-CoV-2 in many parts of the world is creating
conditions for substantial evolutionary changes to the virus,. Here we describe a newly …
conditions for substantial evolutionary changes to the virus,. Here we describe a newly …
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Understanding the molecular basis for immune recognition of SARS-CoV-2 spike
glycoprotein antigenic sites will inform the development of improved therapeutics. We …
glycoprotein antigenic sites will inform the development of improved therapeutics. We …